Improving skin quality and self-esteem in breast cancer survivors on hormone therapy
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
This study is testing how hormone therapy affects skin quality and self-esteem in breast cancer survivors, while also offering skincare advice to see if it helps them feel better about themselves.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT06401889 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effects of aromatase inhibitor therapy on skin quality and self-esteem in breast cancer survivors. Participants will undergo skin assessments using advanced imaging technology and complete surveys to report their self-esteem and quality of life. Additionally, they will receive consultations with an aesthetician to explore skincare interventions. The study aims to measure both objective skin quality changes and subjective improvements in patients' self-reported well-being.
Who should consider this trial
Good fit: Ideal candidates are postmenopausal women aged 18 and older with stage 0-III estrogen receptor-positive breast cancer who are starting aromatase inhibitor therapy.
Not a fit: Patients who have previously taken aromatase inhibitors or are currently using certain facial treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the skin appearance and overall quality of life for breast cancer survivors undergoing aromatase inhibitor therapy.
How similar studies have performed: Other studies have shown positive outcomes in improving quality of life and skin conditions in cancer survivors, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \* Female ≥ 18 years * Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion * Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2) * Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included * Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period * Willing and able to provide consent Exclusion Criteria: * \* Patients who have previously taken AIs * Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent
Where this trial is running
Jacksonville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Leila M. Tolaymat, M.D. — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.